The award was presented on April 9 in recognition of her outstanding research on simplified diazonamide A analogues as anti-cancer agents. Her work represents a significant contribution toward the development of more effective and accessible cancer therapies.
Viktorija Vitkovska’s research addresses one of the key challenges in drug development — maintaining strong biological activity while simplifying complex molecular structures. By advancing innovative microtubule-targeting compounds, her work opens new possibilities for scalable and impactful anticancer treatments.
By supporting the Solomon Hiller Award, Olpha reaffirms its commitment to advancing science and fostering the next generation of researchers. The company believes that investing in research and innovation is essential for developing solutions that improve patients’ lives worldwide.